Kalymin 10 N (Pyridostigmine Bromide)

Pyridostigmine bromide reversibly inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By slowing this breakdown, the drug increases acetylcholine levels at neuromuscular junctions, enhancing nerve‑to‑muscle signaling and improving muscle strength.

The specific dose of Kalymin 10 N is determined by the prescribing clinician based on the patient’s condition, severity, age, renal function and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Kalymin 10 N, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kalymin 10 N (pyridostigmine bromide) is a reversible, peripherally acting anticholinesterase, similar to neostigmine but with a longer duration of action and fewer central nervous system effects. It is often preferred for chronic management of myasthenia gravis due to its oral formulation and tolerability profile.

Kalymin 10 N should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Kalymin 10 N is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare provider. Dosing times are individualized and may be spread throughout the day to maintain stable drug levels.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as profound bradycardia, bronchospasm, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience these symptoms.

Kalymin 10 N should be avoided in individuals with known hypersensitivity to pyridostigmine bromide or other anticholinesterases, in patients with severe asthma or chronic obstructive pulmonary disease where increased secretions could worsen breathing, and in those with certain cardiac conduction disorders unless closely monitored.